BRPI0607529A2 - compostos de azol neuroterapêuticos - Google Patents
compostos de azol neuroterapêuticosInfo
- Publication number
- BRPI0607529A2 BRPI0607529A2 BRPI0607529-0A BRPI0607529A BRPI0607529A2 BR PI0607529 A2 BRPI0607529 A2 BR PI0607529A2 BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 A2 BRPI0607529 A2 BR PI0607529A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- stroke
- neurotherapeutic
- azole compounds
- hemicrania
- Prior art date
Links
- 150000003851 azoles Chemical class 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTOS DE AZOL NEUROTERAPêUTICOS. Compostos de azol contendo grupo carbamoila e sais farmaceuticamente aceitáveis dos mesmos são descritos. Os compostos são anticonvulsivos eficazes que são usados no tratamento de distúrbios do sistema nervoso central, especialmente como ansiedade, depressão, convulsão, epilepsia, hemicrânia, distúrbio bipolar, abuso de droga, fumo, ADHD, obesidade, distúrbio do sono, dor neuropática, acidente vascular cerebral, dano cognitivo, neurodegeneração, acidente vascular cerebral e espasmo muscular.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 | |
| US60/674,530 | 2005-04-22 | ||
| PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0607529A2 true BRPI0607529A2 (pt) | 2009-09-15 |
| BRPI0607529B1 BRPI0607529B1 (pt) | 2021-05-18 |
| BRPI0607529B8 BRPI0607529B8 (pt) | 2021-05-25 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607529A BRPI0607529B8 (pt) | 2005-04-22 | 2006-04-21 | compostos azol e composições farmacêuticas compreendendo os mesmos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (pt) |
| EP (1) | EP1879873B1 (pt) |
| JP (1) | JP5035238B2 (pt) |
| KR (1) | KR101286499B1 (pt) |
| CN (1) | CN101228138B (pt) |
| AR (1) | AR053065A1 (pt) |
| AU (1) | AU2006237798B2 (pt) |
| BR (1) | BRPI0607529B8 (pt) |
| CA (1) | CA2606258C (pt) |
| DK (1) | DK1879873T3 (pt) |
| ES (1) | ES2441765T3 (pt) |
| FI (1) | FIC20210018I1 (pt) |
| MX (1) | MX2007013197A (pt) |
| MY (1) | MY148589A (pt) |
| NL (1) | NL301106I2 (pt) |
| PL (1) | PL1879873T3 (pt) |
| PT (1) | PT1879873E (pt) |
| RU (1) | RU2418792C2 (pt) |
| TW (1) | TWI398249B (pt) |
| WO (1) | WO2006112685A1 (pt) |
| ZA (1) | ZA200709994B (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| DK2155736T3 (da) * | 2007-05-14 | 2012-03-12 | Sk Biopharmaceuticals Co Ltd | Ny carbamoyloxyarylalkanoylarylpiperazin- forbindelse, farmaceutiske sammensætninger, omfattende forbindelsen og fremgangsmåde til behandling af smerte, angst og depression ved indgivelse af forbindelsen |
| CN101808987A (zh) | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
| KR101603487B1 (ko) * | 2008-06-05 | 2016-03-17 | 에스케이바이오팜 주식회사 | 3-치환된 프로판아민 화합물 |
| ES2541590T3 (es) * | 2009-06-22 | 2015-07-22 | Sk Biopharmaceuticals Co., Ltd. | Método para la preparación de éster (R)-1-aril-2-tetrazolil-etílico de ácido carbámico |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| MX2012005258A (es) | 2009-11-06 | 2012-06-19 | Sk Biopharmaceuticals Co Ltd | El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad. |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| CN107011229B (zh) * | 2012-01-06 | 2019-11-05 | 诺华股份有限公司 | 杂环化合物和它们的使用方法 |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| US11571410B2 (en) * | 2016-12-14 | 2023-02-07 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| CN110475544B (zh) * | 2016-12-14 | 2024-03-01 | 爱思开生物制药株式会社 | 包含氨基甲酸酯化合物的口腔崩解片 |
| AU2017374459B2 (en) * | 2016-12-14 | 2023-04-27 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome |
| US11147798B2 (en) | 2016-12-14 | 2021-10-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| KR102635931B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| DK3556349T3 (da) * | 2016-12-14 | 2022-01-03 | Sk Biopharmaceuticals Co Ltd | Parenteralt flydende præparat omfattende en carbamatforbindelse |
| US11389429B2 (en) | 2017-11-14 | 2022-07-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating myotonia |
| CN111432813B (zh) | 2017-11-14 | 2024-01-09 | 爱思开生物制药株式会社 | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 |
| KR102739580B1 (ko) * | 2017-11-14 | 2024-12-06 | 에스케이바이오팜 주식회사 | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR20200074156A (ko) * | 2017-11-14 | 2020-06-24 | 에스케이바이오팜 주식회사 | 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도 |
| US20200352907A1 (en) | 2017-11-14 | 2020-11-12 | Sk Biopharmaceuticals Co., Ltd. | Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure |
| US20200268711A1 (en) | 2017-11-14 | 2020-08-27 | Sk Biopharmaceuticals Co., Ltd. | Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome |
| PL3854391T3 (pl) | 2018-09-21 | 2024-06-24 | Sk Biopharmaceuticals Co., Ltd. | Związek karbaminianowy i zastosowanie preparatu zawierającego ten związek do zapobiegania, łagodzenia lub leczenia ostrego zaburzenia stresowego lub zespołu stresu pourazowego |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
| EP3868375A4 (en) * | 2018-10-19 | 2022-06-29 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| EP4062906A4 (en) * | 2019-11-22 | 2024-01-03 | SK Biopharmaceuticals Co., Ltd. | ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND METHOD FOR PREPARING THIS COMPOSITION |
| CN116322641A (zh) | 2020-08-06 | 2023-06-23 | 爱思开生物制药株式会社 | 包含氨基甲酸酯化合物的固体口服组合物及其制备方法 |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| JP3113678B2 (ja) * | 1991-08-22 | 2000-12-04 | ワーナー−ランバート・コンパニー | アミドテトラゾールａｃａｔ阻害剤 |
| KR100912521B1 (ko) * | 2001-06-25 | 2009-08-18 | 에스케이 주식회사 | 2-헤테로시클릭-1,2-에탄디올의 카바메이트 |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en active Application Filing
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1879873A4 (en) | 2011-06-15 |
| PL1879873T3 (pl) | 2014-03-31 |
| TWI398249B (zh) | 2013-06-11 |
| JP5035238B2 (ja) | 2012-09-26 |
| KR20080005437A (ko) | 2008-01-11 |
| TW200722085A (en) | 2007-06-16 |
| NL301106I1 (nl) | 2021-06-02 |
| WO2006112685A1 (en) | 2006-10-26 |
| EP1879873B1 (en) | 2013-10-09 |
| AR053065A1 (es) | 2007-04-18 |
| FIC20210018I1 (fi) | 2021-06-14 |
| US20060258718A1 (en) | 2006-11-16 |
| JP2008538557A (ja) | 2008-10-30 |
| ZA200709994B (en) | 2008-11-26 |
| PT1879873E (pt) | 2014-01-03 |
| EP1879873A1 (en) | 2008-01-23 |
| NL301106I2 (nl) | 2021-08-03 |
| BRPI0607529B1 (pt) | 2021-05-18 |
| AU2006237798B2 (en) | 2012-07-12 |
| CA2606258A1 (en) | 2006-10-26 |
| RU2007143073A (ru) | 2009-05-27 |
| ES2441765T3 (es) | 2014-02-06 |
| MX2007013197A (es) | 2008-02-12 |
| BRPI0607529B8 (pt) | 2021-05-25 |
| CN101228138A (zh) | 2008-07-23 |
| RU2418792C2 (ru) | 2011-05-20 |
| US7598279B2 (en) | 2009-10-06 |
| MY148589A (en) | 2013-05-15 |
| AU2006237798A1 (en) | 2006-10-26 |
| CA2606258C (en) | 2014-01-14 |
| CN101228138B (zh) | 2012-11-21 |
| DK1879873T3 (da) | 2013-12-09 |
| KR101286499B1 (ko) | 2013-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607529A2 (pt) | compostos de azol neuroterapêuticos | |
| BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CL2008002246A1 (es) | Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion. | |
| CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
| WO2009035473A3 (en) | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders | |
| UA98629C2 (ru) | Соединения и способ модуляции киназ | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| BRPI0814529A2 (pt) | Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central. | |
| BRPI0918868B8 (pt) | compostos moduladores do receptor de nmda e composições compreendendo os mesmos | |
| EP2698166A3 (en) | Complement inhibition for improved nerve regeneration | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BRPI0812740A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo. | |
| MX2010003948A (es) | N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas. | |
| TW200719883A (en) | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof | |
| WO2009108376A3 (en) | Contrast agents for applications including perfusion imaging | |
| MX2010004003A (es) | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. | |
| BRPI0515528A (pt) | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central | |
| EP4086249A3 (en) | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
| BRPI1014222A2 (pt) | composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar | |
| IL190831A0 (en) | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion | |
| UA97401C2 (ru) | Экструдат с улучшенной маскировкой вкуса | |
| BRPI0812366A2 (pt) | composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |